Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 8.39 billion. The enterprise value is 6.36 billion.
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Oct 15, 2026 |
Share Statistics
Sansure Biotech has 568.11 million shares outstanding. The number of shares has decreased by -13.34% in one year.
| Current Share Class | 568.11M |
| Shares Outstanding | 568.11M |
| Shares Change (YoY) | -13.34% |
| Shares Change (QoQ) | +9.33% |
| Owned by Insiders (%) | 38.79% |
| Owned by Institutions (%) | 9.01% |
| Float | 295.70M |
Valuation Ratios
The trailing PE ratio is 77.17 and the forward PE ratio is 33.80.
| PE Ratio | 77.17 |
| Forward PE | 33.80 |
| PS Ratio | 5.08 |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 35.03 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | 56.99 |
| EV / Sales | 3.86 |
| EV / EBITDA | 21.19 |
| EV / EBIT | 136.68 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.54, with a Debt / Equity ratio of 0.21.
| Current Ratio | 4.54 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 5.01 |
| Debt / FCF | n/a |
| Interest Coverage | 1.73 |
Financial Efficiency
Return on equity (ROE) is 0.97% and return on invested capital (ROIC) is 0.80%.
| Return on Equity (ROE) | 0.97% |
| Return on Assets (ROA) | 0.31% |
| Return on Invested Capital (ROIC) | 0.80% |
| Return on Capital Employed (ROCE) | 0.55% |
| Weighted Average Cost of Capital (WACC) | 6.12% |
| Revenue Per Employee | 775,266 |
| Profits Per Employee | 52,474 |
| Employee Count | 2,064 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.05 |
Taxes
In the past 12 months, Sansure Biotech has paid 13.99 million in taxes.
| Income Tax | 13.99M |
| Effective Tax Rate | 16.74% |
Stock Price Statistics
The stock price has decreased by -32.63% in the last 52 weeks. The beta is 0.49, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -32.63% |
| 50-Day Moving Average | 15.89 |
| 200-Day Moving Average | 16.80 |
| Relative Strength Index (RSI) | 34.93 |
| Average Volume (20 Days) | 3,117,580 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.65 billion and earned 111.66 million in profits. Earnings per share was 0.19.
| Revenue | 1.65B |
| Gross Profit | 1.17B |
| Operating Income | 46.56M |
| Pretax Income | 83.59M |
| Net Income | 111.66M |
| EBITDA | 292.54M |
| EBIT | 46.56M |
| Earnings Per Share (EPS) | 0.19 |
Full Income Statement Balance Sheet
The company has 3.62 billion in cash and 1.51 billion in debt, with a net cash position of 2.12 billion or 3.73 per share.
| Cash & Cash Equivalents | 3.62B |
| Total Debt | 1.51B |
| Net Cash | 2.12B |
| Net Cash Per Share | 3.73 |
| Equity (Book Value) | 7.06B |
| Book Value Per Share | 12.26 |
| Working Capital | 3.84B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 239.40 million and capital expenditures -350.79 million, giving a free cash flow of -111.39 million.
| Operating Cash Flow | 239.40M |
| Capital Expenditures | -350.79M |
| Depreciation & Amortization | 245.98M |
| Net Borrowing | 400.11M |
| Free Cash Flow | -111.39M |
| FCF Per Share | -0.20 |
Full Cash Flow Statement Margins
Gross margin is 70.95%, with operating and profit margins of 2.82% and 6.77%.
| Gross Margin | 70.95% |
| Operating Margin | 2.82% |
| Pretax Margin | 5.07% |
| Profit Margin | 6.77% |
| EBITDA Margin | 17.73% |
| EBIT Margin | 2.82% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.53, which amounts to a dividend yield of 3.56%.
| Dividend Per Share | 0.53 |
| Dividend Yield | 3.56% |
| Dividend Growth (YoY) | -2.05% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 163.08% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 13.34% |
| Shareholder Yield | 16.90% |
| Earnings Yield | 1.30% |
| FCF Yield | -1.33% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
Sansure Biotech has an Altman Z-Score of 3.85 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.85 |
| Piotroski F-Score | 4 |